By most measures, investors have reason to be skeptical about vaccine specialist Novavax (NASDAQ:NVAX). Once heralded as a key player in the race to find a solution for the COVID-19 disaster, Novavax shares collapsed as fears of the virus faded sharply. Since then, the company has struggled for relevance. While very few experts will see […]